HIGHLIGHTS
- who: . et al. from the The Ohio State University, United States have published the article: Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review, in the Journal: (JOURNAL)
SUMMARY
In the past decade, treatment based on precision medicine or individualized treatment has changed the outlook of many types of cancers (Nelson et_al, 2021). Nivolumab combined with chemotherapy significantly improved the progression-free survival (PFS) and overall survival (OS) in the first-line treatment of HER2-negative gastric cancer patients (Janjigian . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.